Pathogenic Gut Flora in Patients With Chronic Heart Failure
- PMID: 26682791
- DOI: 10.1016/j.jchf.2015.10.009
Pathogenic Gut Flora in Patients With Chronic Heart Failure
Abstract
Objectives: The goal of this study was to measure the presence of pathogenic gut flora and intestinal permeability (IP) and their correlations with disease severity, venous blood congestion, and inflammation in patients with chronic heart failure (CHF).
Background: Evidence suggests that translocation of gut flora and/or their toxins from the intestine to the bloodstream is a possible trigger of systemic CHF inflammation. However, the relation between pathogenic gut flora and CHF severity, as well as IP, venous blood congestion as right atrial pressure (RAP), and/or systemic inflammation (C-reactive protein [CRP]), is still unknown.
Methods: This study analyzed 60 well-nourished patients in stable condition with mild CHF (New York Heart Association [NYHA] functional class I to II; n = 30) and moderate to severe CHF (NYHA functional class III to IV; n = 30) and matched healthy control subjects (n = 20). In all subjects, the presence and development in the feces of bacteria and fungi (Candida species) were measured; IP according to cellobiose sugar test results was documented. The study data were then correlated with RAP (echocardiography) and systemic inflammation.
Results: Compared with normal control subjects, the entire CHF population had massive quantities of pathogenic bacteria and Candida such as Campylobacter (85.3 ± 3.7 CFU/ml vs. 1.0 ± 0.3 CFU/ml; p < 0.001), Shigella (38.9 ± 12.3 CFU/ml vs. 1.6 ± 0.2 CFU/ml; p < 0.001), Salmonella (31.3 ± 9.1 CFU/ml vs 0 CFU/ml; p < 0.001), Yersinia enterocolitica (22.9 ± 6.3 CFU/ml vs. 0 CFU/ml; p < 0.0001), and Candida species (21.3 ± 1.6 CFU/ml vs. 0.8 ± 0.4 CFU/ml; p < 0.001); altered IP (10.2 ± 1.2 mg vs. 1.5 ± 0.8 mg; p < 0.001); and increased RAP (12.6 ± 0.6 mm Hg) and inflammation (12.5 ± 0.6 mg/dl). These variables were more pronounced in patients with moderate to severe NYHA functional classes than in patients with the mild NYHA functional class. Notably, IP, RAP, and CRP were mutually interrelated (IP vs. RAP, r = 0.55; p < 0.0001; IP vs. CRP, r = 0.78; p < 0.0001; and RAP vs. CRP, r = 0.78; p < 0.0001).
Conclusions: This study showed that patients with CHF may have intestinal overgrowth of pathogenic bacteria and Candida species and increased IP associated with clinical disease severity, venous blood congestion, and inflammation.
Keywords: chronic heart failure; gut flora; inflammation; intestinal permeability.
Copyright © 2016 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
Comment in
-
Heart failure: Gut flora--pathogenic role in chronic heart failure.Nat Rev Cardiol. 2016 Feb;13(2):61. doi: 10.1038/nrcardio.2015.200. Epub 2015 Dec 24. Nat Rev Cardiol. 2016. PMID: 26701213 No abstract available.
-
We Are Not Alone: Understanding the Contributions of Intestinal Microbial Communities and the Congested Gut in Heart Failure.JACC Heart Fail. 2016 Mar;4(3):228-9. doi: 10.1016/j.jchf.2015.12.004. Epub 2016 Feb 10. JACC Heart Fail. 2016. PMID: 26874394 No abstract available.
Similar articles
-
Altered intestinal function in patients with chronic heart failure.J Am Coll Cardiol. 2007 Oct 16;50(16):1561-9. doi: 10.1016/j.jacc.2007.07.016. Epub 2007 Oct 1. J Am Coll Cardiol. 2007. PMID: 17936155
-
Impaired resolution of inflammation in human chronic heart failure.Eur J Clin Invest. 2014 Jun;44(6):527-38. doi: 10.1111/eci.12265. Epub 2014 Apr 22. Eur J Clin Invest. 2014. PMID: 24673112
-
Studies on bacterial endotoxin and intestinal absorption function in patients with chronic heart failure.Int J Cardiol. 2012 May 17;157(1):80-5. doi: 10.1016/j.ijcard.2010.12.016. Epub 2010 Dec 28. Int J Cardiol. 2012. PMID: 21190739
-
The gut and intestinal bacteria in chronic heart failure.Curr Drug Metab. 2009 Jan;10(1):22-8. doi: 10.2174/138920009787048374. Curr Drug Metab. 2009. PMID: 19149510 Review.
-
[Fungi in the gut - the gut mycobiome].Z Gastroenterol. 2017 Aug;55(8):772-778. doi: 10.1055/s-0043-112657. Epub 2017 Aug 10. Z Gastroenterol. 2017. PMID: 28799153 Review. German.
Cited by
-
Role of gut microbiota in doxorubicin-induced cardiotoxicity: from pathogenesis to related interventions.J Transl Med. 2024 May 8;22(1):433. doi: 10.1186/s12967-024-05232-5. J Transl Med. 2024. PMID: 38720361 Free PMC article. Review.
-
Metabolomic insights in advanced cardiomyopathy of chronic chagasic and idiopathic patients that underwent heart transplant.Sci Rep. 2024 Apr 29;14(1):9810. doi: 10.1038/s41598-024-53875-7. Sci Rep. 2024. PMID: 38684702 Free PMC article.
-
The Role of Gut Microbiota and Its Metabolites in Patients with Heart Failure.Biomedicines. 2024 Apr 18;12(4):894. doi: 10.3390/biomedicines12040894. Biomedicines. 2024. PMID: 38672248 Free PMC article. Review.
-
The Correlation Between Heart Failure and Gut Microbiome Metabolites.Infect Microbes Dis. 2020 Nov 4;2(4):136-143. doi: 10.1097/IM9.0000000000000042. eCollection 2020 Dec. Infect Microbes Dis. 2020. PMID: 38630083 Free PMC article. Review.
-
Associations between the gut microbiome, gut microbiology and heart failure: Current understanding and future directions.Am Heart J Plus. 2022 Jun 11;17:100150. doi: 10.1016/j.ahjo.2022.100150. eCollection 2022 May. Am Heart J Plus. 2022. PMID: 38559891 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous